We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01103180
First Posted: April 14, 2010
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Temple University
Northwestern University
University of Southern Mississippi
Information provided by (Responsible Party):
University of Chicago
  Purpose
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

Condition Intervention Phase
Borderline Personality Disorder Drug: Escitalopram Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: SSRIs and Self-harm in Borderline Personality Disorder

Resource links provided by NLM:


Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • self-harm ideation [ Time Frame: pretreatment to 1-week post treatment ]
    Self-harm ideation will be assessed using electronic diaries throught the trial from one week pre-treatment to one week post-treatment


Secondary Outcome Measures:
  • Depressive symptoms [ Time Frame: pre-treatment to 1 week post-treatment ]
    depressive symptoms will be assessed using weekly interviews and electronic diaries throught the trial from one week pre-treatment to one week post-treatment


Enrollment: 80
Study Start Date: September 2010
Study Completion Date: November 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Escitalopram
10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
Drug: Escitalopram
10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
Other Name: Lexapro
Placebo Comparator: Placebo
Inert placebo (sugar pill) taken daily for eight weeks
Drug: Escitalopram
10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
Other Name: Lexapro

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Borderline Personality Disorder
  • Current Major Depression

Exclusion Criteria:

  • Past 2 months SSRI use
  • Past 6 months non-SSRI antidepressant use
  • Past 2 months initiation of psychotherapy
  • Lifetime bipolar disorder, organic disorder, psychotic disorder
  • Current alcohol or drug dependence
  • Current severe suicidal / homicidal ideation necessitating immediate medical intervention
  • Currently pregnancy or nursing
  • Unable or unwilling to cooperate with study protocol
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01103180


Locations
United States, Illinois
The University of Chicago Hospitals
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Temple University
Northwestern University
University of Southern Mississippi
Investigators
Principal Investigator: Michael S McCloskey, Ph.D Temple University (primary) / University of Chicago
Principal Investigator: Emil F Coccaro, M.D. University of Chicago
  More Information

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT01103180     History of Changes
Other Study ID Numbers: MH084904
First Submitted: April 12, 2010
First Posted: April 14, 2010
Last Update Posted: October 12, 2017
Last Verified: April 2015

Keywords provided by University of Chicago:
Selective Serotonin Reuptake Inhibitor
Escitalopram
Borderline Personality Disorder
Major Depressive Disorder
Self-harm

Additional relevant MeSH terms:
Disease
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders
Citalopram
Serotonin Uptake Inhibitors
Dexetimide
Serotonin
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Serotonin Receptor Agonists